Schematic representation of process for TIL initiation, expansion and testing. Figure S2. Lymphocytic immune infiltrate is insufficient to predict TIL culture success. A) Representative H&E stain from 4 patients, two are classified as 3+ (Top) and two are classified as 1+ (Bottom), TIL culture status is indicated above images. B) Compares average pathology scores of lymphocytic infiltrate between tumors that grew TILs and those that did not. Figure S3. Comparison of two methods to evaluate immune infiltrate. A) Comparison between % CD8 T cell infiltrate and # of CD8 positive cells/mm^2. B) Comparison between # of CD8 positive T cells/mm^2 determined using PerkinElmer and Definiens. The comparisons were done using the identical image. Statis...
Clinical and image data from the melanoma, lung cancer, and colorectal cancer cohorts. Clinical data...
Immunohistochemistry analysis of lymphocyte infiltration in the tumor microenvironment. Two selected...
Figure S1. Kaplan-Meier analysis of overall survival and progression-free survival in the anti-CTLA-...
Supplemental methods. Detailed immunohistochemistry methods for multispectral analysis. (DOCX 20Â kb
(a) Representative flow cytometric analysis on immature and mature DCs. The purple histograms repres...
Figure S1 IA classification of CD8+ lymphocytes. Figure S2 IA classification of elongate CD8+ lympho...
Figure S1. Tregs infiltration in HT29 spheroids. Percentages of Foxp3+CD25+ Tregs among CD4+ T cells...
Immunostain of CD68 in entire tissue of FTC/FA samples. (A) An example of immunohistochemistry analy...
Table S1 Relevant image information for nonclinical sample sets. Table S2 Nonclinical tumor samples,...
Contains fulltext : 173035.pdf (Publisher’s version ) (Open Access)AIMS: The quali...
Figure S1. Representative staining of ILC populations. ILC were gated on lineage negative, CD45+, CD...
Table S1. Clinical and pathological characteristics for eligible patients in the I-SPY cohort. Table...
CD8/PD-L1 dual IHC, quality control; co-registration; details of the automated classification assess...
Figure S1. Representative immunohistochemistry (IHC) staining images for CD8, CD4, CD20 and CD68. Im...
Figure S1. Expression of CD19/CD20, CD79A/B and RAG1/RAG2 in blood cancer cell lines. X axis: 164 bl...
Clinical and image data from the melanoma, lung cancer, and colorectal cancer cohorts. Clinical data...
Immunohistochemistry analysis of lymphocyte infiltration in the tumor microenvironment. Two selected...
Figure S1. Kaplan-Meier analysis of overall survival and progression-free survival in the anti-CTLA-...
Supplemental methods. Detailed immunohistochemistry methods for multispectral analysis. (DOCX 20Â kb
(a) Representative flow cytometric analysis on immature and mature DCs. The purple histograms repres...
Figure S1 IA classification of CD8+ lymphocytes. Figure S2 IA classification of elongate CD8+ lympho...
Figure S1. Tregs infiltration in HT29 spheroids. Percentages of Foxp3+CD25+ Tregs among CD4+ T cells...
Immunostain of CD68 in entire tissue of FTC/FA samples. (A) An example of immunohistochemistry analy...
Table S1 Relevant image information for nonclinical sample sets. Table S2 Nonclinical tumor samples,...
Contains fulltext : 173035.pdf (Publisher’s version ) (Open Access)AIMS: The quali...
Figure S1. Representative staining of ILC populations. ILC were gated on lineage negative, CD45+, CD...
Table S1. Clinical and pathological characteristics for eligible patients in the I-SPY cohort. Table...
CD8/PD-L1 dual IHC, quality control; co-registration; details of the automated classification assess...
Figure S1. Representative immunohistochemistry (IHC) staining images for CD8, CD4, CD20 and CD68. Im...
Figure S1. Expression of CD19/CD20, CD79A/B and RAG1/RAG2 in blood cancer cell lines. X axis: 164 bl...
Clinical and image data from the melanoma, lung cancer, and colorectal cancer cohorts. Clinical data...
Immunohistochemistry analysis of lymphocyte infiltration in the tumor microenvironment. Two selected...
Figure S1. Kaplan-Meier analysis of overall survival and progression-free survival in the anti-CTLA-...